Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Arhalofenate
MBX-102 · 6 trials · 3 indications
Percent change from baseline in serum uric acid in Per Protocol population
| Arm | Type | Description |
|---|---|---|
| Arhalofenate with febuxostat (PK cohort) | EXPERIMENTAL | - |
| Arhalofenate with febuxostat (non-PK cohort) | EXPERIMENTAL | - |
| Arhalofenate 600 mg | EXPERIMENTAL | - |
| Arhalofenate 800 mg | EXPERIMENTAL | - |
| Allopurinol 300 mg; colchicine 0.6 mg | ACTIVE_COMPARATOR | - |
| Allopurinol 300 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Arhalofenate with febuxostat and colchicine | OTHER | - |
| Arhalofenate 400 mg | EXPERIMENTAL | Arhalofenate 400 mg plus allopurinol 300 mg |
| Allopurinol | ACTIVE_COMPARATOR | Placebo plus Allopurinol 300 mg |
| MBX-102 200 mg | EXPERIMENTAL | MBX-102 200 mg once daily for 16 weeks |
| MBX-102 400 mg | EXPERIMENTAL | MBX-102 400 mg once daily for 16 weeks |
| MBX-102 600 mg | EXPERIMENTAL | MBX-102 600 mg once daily for 16 weeks |
| Sugar Pill | PLACEBO_COMPARATOR | Placebo comparator once daily for 16 weeks |
| Actos | ACTIVE_COMPARATOR | Actos 30 mg once daily for 16 weeks |
| Name | Type | Description |
|---|---|---|
| Arhalofenate | DRUG | 800 mg once daily orally for four weeks |
| Febuxostat | DRUG | 40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks |
| Colchicine | DRUG | 0.6 mg daily |
| Arhalofenate 600 mg | DRUG | Arhalofenate 600 mg tablets once daily for 12 weeks |
| Allopurinol 300 mg | DRUG | Allopurinol 300 mg tablets once daily for 12 weeks |
| Colchicine 0.6 mg | DRUG | Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks |
| Placebo | DRUG | Placebo tablets once daily for 12 weeks |
| Arhalofenate 800 mg | DRUG | Arhalofenate 800 mg tablets once daily for 12 weeks |
| Allopurinol | DRUG | Allopurinol 300 mg as active comparator |
| Placebo comparator | DRUG | Matching placebo once daily for 4 weeks |
| MBX-102 | DRUG | MBX-102 200 mg once daily for 16 weeks |
| Actos | DRUG | Actos 30 mg once daily for 16 weeks |
Inclusion Criteria: * Male or female patient, 18 to 75 years of age, inclusive * Known gout diagnosis (per criteria of the American Rheumatism Association) * Has an sUA ≥ 7.5 mg/dL * A female patient must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses f...
Top 16 of 30 competitors
MBX-102 is a small molecule being developed for the treatment of Type 2 Diabetes. It is currently in Phase 2 clinical development and is being studied in patients whose blood sugar is not adequately controlled with insulin therapy.
The specific molecular target of MBX-102 has not been disclosed. It is a small molecule therapeutic being developed for Type 2 Diabetes, but its mechanism of action is not publicly detailed in the available information.
MBX-102 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 Diabetes.
MBX-102 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not yet approved by regulatory authorities. The drug remains investigational and is being studied for its potential use in Type 2 Diabetes.
MBX-102 has one completed clinical trial, identified as NCT00353587. This was a Phase 2, randomized, double-blind, placebo-controlled study that enrolled 396 participants with Type 2 Diabetes who were suboptimally controlled on insulin. The trial was conducted in the United States, Argentina, India, and Israel.
Yes, MBX-102 is also known as Metaglidasen. The clinical trial NCT00353587, which evaluated the drug in Type 2 Diabetes, refers to it as Metaglidasen. Both names refer to the same investigational small molecule being developed by Gilead Sciences.